Analyst picks & changes

IDEC Pharmaceuticals Corp. (IDPH)

Gregory Brown of Vector Securities International repeated a "buy", with a one-year target of $11. He said the start of Phase III trials of IDEC C2B8 in relapsed low grade B cell lymphoma, and the recently announced deal with ...